ArticleJournal of asthma and allergy2025
Optimizing Fluticasone Propionate and Ciclesonide pMDI Delivery: The Protective Role of Valved Holding Chambers Against Inhalation Timing Errors.
Article in Journal of asthma and allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Discoordination between inhalation and pressurized metered-dose inhaler (pMDI) actuation when delivering inhaled corticosteroids (ICS) is a common technique error that can lead to worsened treatment outcomes. Valved holding chambers (VHCs) are thought to improve the delivered dose if inhalation is delayed, but this effect has not been sufficiently quantified. Methods: The aerodynamic particle size distribution of fluticasone propionate (FP) and ciclesonide (CIC) was studied under three conditions: inhalation initiated before actuation without a VHC, inhalation started at actuation without a VHC, and inhalation started at actuation with a VHC. We used a Next Generation Impactor connected to an anatomical adult throat model and a breathing simulator that produced a single, adult-type inhalation. Results: We found that when inhalation was initiated simultaneously with actuation, the effective dose delivered decreased markedly for both FP and CIC compared to when inhalation was begun correctly, ie, before actuation. However, when a VHC was used and inhalation was started at actuation, delivered dose improved substantially for both medications. This protective effect of the VHC was especially pronounced for CIC, with both the fraction of particles in the 1-5 µm range and those under 1 µm returning to the same levels as when inhalation was initiated correctly. Discussion: Although our study was conducted in vitro and did not involve patients, the findings likely have relevance for clinical practice. Therefore, promoting the use of VHCs in both children and adults may be beneficial, but this should be confirmed in clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.